140 related articles for article (PubMed ID: 37505974)
1. Severe acute respiratory syndrome coronavirus 2 infection does not worsen the course of inflammatory bowel disease in the long term.
Neri B; D'Agostini G; Salvatori S; Mossa M; Bettin F; Mancone R; Marafini I; Lolli E; Calabrese E; Monteleone G; Biancone L
Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):948-954. PubMed ID: 37505974
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Igg seroprevalence in IBD patients treated with biologics: first vs. second pandemic wave in a prospective study.
Mossa M; Neri B; Montesano L; Salvatori S; Marafini I; Scucchi L; Lolli E; Massoud R; Petruzziello C; Bernardini S; Calabrese E; Monteleone G; Biancone L
Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3787-3796. PubMed ID: 35647861
[TBL] [Abstract][Full Text] [Related]
3. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.
Scucchi L; Neri B; Sarmati L; Mossa M; Sena G; Massoud R; Petruzziello C; Musumeci M; Marafini I; Calabrese E; Lolli E; Bernardini S; Andreoni M; Monteleone G; Biancone L
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2418-2424. PubMed ID: 33755981
[TBL] [Abstract][Full Text] [Related]
4. High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India.
Kante B; Vuyyuru SK; Gupta R; Dwivedi T; Kumar P; Mundhra S; Golla R; Virmani S; Verma M; Makharia G; Ahuja V; Kedia S
Indian J Gastroenterol; 2023 Feb; 42(1):70-78. PubMed ID: 36738383
[TBL] [Abstract][Full Text] [Related]
5. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
[TBL] [Abstract][Full Text] [Related]
6. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
[TBL] [Abstract][Full Text] [Related]
7. Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain.
Guerra I; Algaba A; Jiménez L; Mar Aller M; Garza D; Bonillo D; Molina Esteban LM; Bermejo F
Inflamm Bowel Dis; 2021 Jan; 27(1):25-33. PubMed ID: 32830267
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis.
Sung KY; Chang TE; Wang YP; Lin CC; Chang CY; Hou MC; Lu CL
J Chin Med Assoc; 2022 Apr; 85(4):421-430. PubMed ID: 34974509
[TBL] [Abstract][Full Text] [Related]
9. Serological response to vaccination against coronavirus disease-19 in patients with inflammatory bowel disease.
Mathur A; Sahu S; Rai S; Ghoshal U; Ghoshal UC
Indian J Gastroenterol; 2023 Feb; 42(1):64-69. PubMed ID: 36598745
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves.
Bezzio C; Vernero M; Costa S; Armuzzi A; Fiorino G; Ardizzone S; Roselli J; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Alimenti E; Balestrieri P; Ricci C; Cappello M; Felice C; Coppini F; Alvisi P; Di Luna I; Gerardi V; Variola A; Mazzuoli S; Lenti MV; Saibeni S;
BMC Gastroenterol; 2023 Jul; 23(1):230. PubMed ID: 37407913
[TBL] [Abstract][Full Text] [Related]
11. Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel Disease.
De Nicolò A; Cusato J; Bezzio C; Saibeni S; Vernero M; Disabato M; Caviglia GP; Ianniello A; Manca A; D'Avolio A; Ribaldone DG
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615826
[TBL] [Abstract][Full Text] [Related]
12. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
[TBL] [Abstract][Full Text] [Related]
13. Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study.
Papa A; Scaldaferri F; Covino M; Tursi A; Furfaro F; Mocci G; Lopetuso LR; Maconi G; Bibbò S; Fiorani M; Laterza L; Mignini I; Napolitano D; Parisio L; Pizzoferrato M; Privitera G; Pugliese D; Schepis T; Schiavoni E; Settanni CR; Vetrone LM; Armuzzi A; Danese S; Gasbarrini A
Biomedicines; 2022 Apr; 10(4):. PubMed ID: 35453593
[TBL] [Abstract][Full Text] [Related]
14. Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research.
Nakase H; Matsumoto T; Matsuura M; Iijima H; Matsuoka K; Ohmiya N; Ishihara S; Hirai F; Wagatsuma K; Yokoyama Y; Hisamatsu T
Digestion; 2021; 102(5):814-822. PubMed ID: 32892197
[TBL] [Abstract][Full Text] [Related]
15. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System.
Khan N; Mahmud N; Trivedi C; Reinisch W; Lewis JD
Gut; 2021 Sep; 70(9):1657-1664. PubMed ID: 33753416
[TBL] [Abstract][Full Text] [Related]
17. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications.
Khan N; Mahmud N
Gastroenterology; 2021 Sep; 161(3):827-836. PubMed ID: 34048782
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory bowel diseases and the clinical course of coronavirus disease 2019 - a Polish single-centre experience from the pre-vaccine era.
Banasik E; Dobrowolska A; Kołodziejczak B; Eder P
Prz Gastroenterol; 2023; 18(4):409-415. PubMed ID: 38572464
[TBL] [Abstract][Full Text] [Related]
20. Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis.
Chen L; Hu K; Cheng C; Hu Q; Zhang L; An T; Guo Y; Chen S; Duan G
Int J Colorectal Dis; 2022 Nov; 37(11):2277-2289. PubMed ID: 36271206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
